2021 年第 2 期 第 16 卷

卵巢癌患者四项血清肿瘤标志物水平的变化及意义

Changes and significance of four serum tumor markers in patients with ovarian cancer

作者：陈艳梅1张春蕾2龚振英3赵洪焕1徐进霞1李涛4孙星5韩素桂1

英文作者：Chen Yanmei1 Zhang Chunlei2 Gong Zhenying3 Zhao Honghuan1 Xu Jinxia1 Li Tao4 Sun Xing5 Han Sugui1 

单位：1河北省唐山市人民医院核医学检验科063001；2河北省唐山市人民医院检验科063001；3河北省滦州市中医医院妇产科063700；4河北省唐山市人民医院功能检查科063001；5河北省唐山市人民医院妇产科063001

英文单位：1Nuclear Medicine Laboratory Tangshan People′s Hospital Hebei Province Tangshan 063001 China; 2Department of Laboratory Tangshan People′s Hospital Hebei Province Tangshan 063001 China; 3Department of Obstetrics and Gynecology Luanzhou Hospital of Traditional Chinese Medicine Hebei Province Luanzhou 063700 China; 4Department of Functional Examination Tangshan People′s Hospital Hebei Province Tangshan 063001 China; 5Department of Obstetrics and Gynecology Tangshan People′s Hospital Hebei Province Tangshan 063001 China

关键词：卵巢癌；人附睾蛋白4；甲胎蛋白；糖类抗原724；糖类抗原125

英文关键词：Ovariancancer;Humanepididymisprotein4;Alpha-fetoprotein;Carbohydrateantigen724;Carbohydrateantigen125 

• 摘要：

• 目的 探讨卵巢癌患者血清人附睾蛋白4（HE4）、甲胎蛋白、糖类抗原724和糖类抗原125水平的变化及意义。方法 选取河北省唐山市人民医院2016年5月至2019年5月收治的90例卵巢癌患者（卵巢癌组）和92例卵巢良性肿瘤患者（良性肿瘤组），另选取同期体格检查健康者90名为健康对照组。比较3组研究对象和不同国际妇产科联盟（FIGO）分期卵巢癌患者血清HE4、甲胎蛋白、糖类抗原724和糖类抗原125水平，比较4项血清肿瘤标志物单独和联合检测对卵巢癌的诊断价值。结果 卵巢癌组血清HE4、甲胎蛋白、糖类抗原724和糖类抗原125水平均高于良性肿瘤组［(190±101) pmol/L比（67±30）pmol/L，(9.6±5.9) μg/L比（5.4±3.4）μg/L，(14.0±10.7)kU/L比（3.2±2.4）kU/L，(158±76)kU/L比（57±34）kU/L］和健康对照组，且良性肿瘤组上述4项血清肿瘤标志物水平均高于健康对照组（均P<0.05）。卵巢癌患者血清HE4、甲胎蛋白、糖类抗原724和糖类抗原125水平随FIGO分期的增加而升高，差异均有统计学意义（均P<0.05）。血清HE4、甲胎蛋白、糖类抗原724和糖类抗原125联合检测对卵巢癌患者的敏感度、特异度和准确性均高于单一检测。结论 卵巢癌患者血清HE4、甲胎蛋白、糖类抗原724和糖类抗原125水平均高于良性肿瘤患者和健康对照人群，卵巢癌患者4项血清肿瘤标志物水平随FIGO分期的增加而逐渐升高，4项血清肿瘤标志物联合检测对卵巢癌的诊断价值高于各指标单独检测。

• Objective To explore the changes and significance of serum human epididymal protein 4 (HE4), alpha-fetoprotein (AFP), carbohydrate antigen (CA) 724 and CA125 in patients with ovarian cancer. Methods From May 2016 to May 2019, 90 patients with ovarian cancer (ovarian cancer group) and 92 patients with benign ovarian tumor (benign tumor group) treated in Tangshan People′s Hospital of Hebei Province were selected, and 90 healthy persons with physical examination in the same period were selected as healthy control group. The levels of serum HE4, AFP, CA724 and CA125 were compared among three groups, and the levels of four serum tumor markers in patients with ovarian cancer in different stages of the International Federation of Obstetrics and Gynecology (FIGO) were compared. The diagnostic value of the four serum tumor markers by single and combined detection were compared. Results  The levels of serum HE4, AFP, CA724 and CA125 in the ovarian cancer group were higher than those in the benign tumor group ［(190±101)pmol/L vs （67±30）pmol/L，(9.6±5.9)μg/L vs （5.4±3.4）μg/L，(14.0±10.7)kU/L vs （3.2±2.4）kU/L，(158±76)kU/L vs （57±34）kU/L］and the healthy control group, and those in the benign tumor group were higher than those in the healthy control group (all P<0.05).The levels of serum HE4, AFP, CA724 and CA125 increased with the increase of FIGO stage in patients with ovarian cancer (all P<0.05).The sensitivity, specificity and accuracy of combined detection of serum HE4, AFP, CA724 and CA125 in patients with ovarian cancer was higher than those single detection (P<0.05). Conclusions The levels of HE4, AFP, CA724 and CA125 of ovarian cancer patients are higher than those of ovarian benign tumors patients and healthy control people. With the increase of FIGO stage of ovarian cancer patients, the levels of serum HE4, AFP, CA724 and CA125 gradually increase. The sensitivity, specificity and accuracy of combined detection of serum HE4, AFP, CA724 and CA125 are higher than that of single detection.